Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atomega
- Development stage
- Unknown
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atomega (KI-3108) is a fixed-dose combination (FDC) therapy developed by Kuhnil Pharmaceuticals for the management of combined hyperlipidemia. It integrates atorvastatin, a potent HMG-CoA reductase inhibitor (statin), with omega-3-acid ethyl esters (comprising EPA and DHA). Atorvastatin reduces LDL cholesterol and triglycerides by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, while omega-3-acid ethyl esters lower serum triglycerides by inhibiting hepatic synthesis of VLDL and increasing triglyceride clearance through mechanisms involving PPAR-alpha activation and DGAT inhibition. This combination is particularly indicated for patients who require simultaneous control of both LDL-C and triglyceride levels. Atomega was approved by the South Korean Ministry of Food and Drug Safety (MFDS) in 2020.
- Brand names
- Atomega
- Other names
- Atorvastatin + Omega-3-acid ethyl esters
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)DGAT1 (Diacylglycerol O-acyltransferase 1)
Beyond the preview
Go deeper on Atomega.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atomega.